Skip to main content

Advertisement

SpringerLink
Log in

A Dissemination and Implementation Science Approach to the Epidemic of Opioid Use Disorder in the United States

  • The Global Epidemic (SH Vermund, Section Editor)
  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review aims to (1) conceptualize the complexity of the opioid use disorder epidemic using a conceptual model grounded in the disease continuum and corresponding levels of prevention and (2) summarize a select set of interventions for the prevention and treatment of opioid use disorder.

Recent Findings

Epidemiologic data indicate non-medical prescription and illicit opioid use have reached unprecedented levels, fueling an opioid use disorder epidemic in the USA. A problem of this magnitude is rooted in multiple supply- and demand-side drivers, the combined effect of which outweighs current prevention and treatment efforts. Multiple primary, secondary, and tertiary prevention interventions, both evidence-informed and evidence-based, are available to address each point along the disease continuum—non-use, initiation, dependence, addiction, and death.

Summary

If interventions grounded in the best available evidence are disseminated and implemented across the disease continuum in a coordinated and collaborative manner, public health systems could be increasingly effective in responding to the epidemic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Office of National Drug Control Policy. Epidemic: responding to America's prescription drug abuse crisis. Executive Office of the President of the United States, Washington, DC. 2011. https://obamawhitehouse.archives.gov/sites/default/files/ondcp/policy-and-research/rx_abuse_plan.pdf.

  2. Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559–74. https://doi.org/10.1146/annurev-publhealth-031914-122957.

    Article  PubMed  Google Scholar 

  3. Manchikanti L, Helm S, Fellows B, Janata JW, Pampati V, Grider JS, et al. Opioid epidemic in the United States. Pain Physician. 2012;15:ES9–ES38.

    PubMed  Google Scholar 

  4. Maxwell JC. The prescription drug epidemic in the United States: a perfect storm. Drug Alcohol Rev. 2011;30(3):264–70. https://doi.org/10.1111/j.1465-3362.2011.00291.x.

    Article  PubMed  Google Scholar 

  5. National Institute on Drug Abuse. Prescription drug abuse (NIDA Research Report Series, NIH Publication Number 11–4881). Bethesda, MD: National Institute on Drug Abuse, National Institutes of Health, U.S. Department of Health and Human Services; 2011.

  6. Buchanich JM, Balmert LC, Burke DS. Exponential growth of the USA overdose epidemic. bioRxiv. 2017;134403. doi:https://doi.org/10.1101/134403

  7. Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15–4927, NSDUH Series H-50). Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015.

  8. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment episode data set (TEDS): 2003–2013. National admissions to substance abuse treatment services (BHSIS series S-75, HHS publication no. (SMA) 15–4934). Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015.

  9. Tolia VN, Patrick SW, Bennett MM, Murthy K, Sousa J, Smith PB, et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med. 2015;372(22):2118–26. https://doi.org/10.1056/NEJMsa1500439.

    Article  PubMed  Google Scholar 

  10. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers--United States, 1999--2008. MMWR Morb Mortal Wkly Rep. 2011;60(43):1487–92.

  11. Centers for Disease Control and Prevention. Opioid painkiller prescribing: where you live makes a difference. 2014. http://www.cdc.gov/vitalsigns/opioid-prescribing/. Accessed 7 May 2016.

  12. Paulozzi LJ, Mack KA, Hockenberry JM. Vital signs: variation among states in prescribing of opioid pain relievers and benzodiazepines--United States, 2012. MMWR Morb Mortal Wkly Rep. 2014;63(26):563–8.

    PubMed  PubMed Central  Google Scholar 

  13. Van Zee A. The promotion and marketing of OxyContin: commercial triumph, public health tragedy. Am J Public Health. 2009;99(2):221–7. https://doi.org/10.2105/AJPH.2007.131714.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Alexander G, Kruszewski SP, Webster DW. Rethinking opioid prescribing to protect patient safety and public health. JAMA. 2012;308(18):1865–6. https://doi.org/10.1001/jama.2012.14282.

    Article  CAS  PubMed  Google Scholar 

  15. Campbell J. APS 1995 presidential address. Pain Forum. 1996;5:85–8.

    Article  Google Scholar 

  16. Morone NE, Weiner DK. Pain as the 5th vital sign: exposing the vital need for pain education. Clin Ther. 2013;35(11):1728–32. https://doi.org/10.1016/j.clinthera.2013.10.001.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Office of National Drug Control Policy. Fact sheet: a response to the epidemic of prescription drug abuse. Executive Office of the President, Washington, DC. 2011. https://obamawhitehouse.archives.gov/sites/default/files/ondcp/Fact_Sheets/prescription_drug_abuse_fact_sheet_4-25-11.pdf.

  18. Nargiso JE, Ballard EL, Skeer MR. A systematic review of risk and protective factors associated with nonmedical use of prescription drugs among youth in the United States: a social ecological perspective. J Stud Alcohol Drugs. 2015;76(1):5–20.

    Article  PubMed  Google Scholar 

  19. Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: summary of national findings (NSDUH series H-48, HHS publication no. (SMA) 14–4863). Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014.

  20. National Academies of Sciences, Engineering, and Medicine. Understanding stigma of mental and substance use disorders. In: Ending discrimination against people with mental and substance use disorders: the evidence for stigma change. Washington, DC: The National Academies of Press; 2016.

  21. Rüsch N, Thornicroft G. Does stigma impair prevention of mental disorders? Br J Psychiatry. 2014;204(4):249–51.

    Article  PubMed  Google Scholar 

  22. Barry CL, McGinty EE, Pescosolido BA, Goldman HH. Stigma, discrimination, treatment effectiveness, and policy: public views about drug addiction and mental illness. Psychiatr Serv. 2014;65(10):1269–72. https://doi.org/10.1176/appi.ps.201400140.

    Article  PubMed  PubMed Central  Google Scholar 

  23. National Institute on Drug Abuse. DrugFacts: understanding drug use and addiction. 2016. https://www.drugabuse.gov/publications/drugfacts/understanding-drug-use-addiction. Accessed 7 May 2016.

  24. Winstanley EL, Clark A, Feinberg J, Wilder CM. Barriers to implementation of opioid overdose prevention programs in Ohio. Subst Abus. 2016;37(1):42–6. https://doi.org/10.1080/08897077.2015.1132294.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs (Treatment Improvement Protocol (TIP) Series 43, HHS Publication No. (SMA) 12–4214). Rockville, MD: Substance Abuse and Mental Health Services Administration; 2005.

  26. Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374(2):154–63. https://doi.org/10.1056/NEJMra1508490.

    Article  CAS  PubMed  Google Scholar 

  27. Centers for Disease Control and Prevention. Prescription drug overdose data. 2016. http://www.cdc.gov/drugoverdose/data/overdose.html. Accessed 2 March 2016.

  28. Peters PJ, Pontones P, Hoover KW, Patel MR, Galang RR, Shields J, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014–2015. N Engl J Med. 2016;375(3):229–39. https://doi.org/10.1056/NEJMoa1515195.

    Article  CAS  PubMed  Google Scholar 

  29. Broz D. Large community outbreak of HIV-1 linked to injection drug use of oxymorphone - Indiana, 2015. Southern opioid epidemic: crafting an effective public health response symposium; Emory University, Atlanta, GA 2016.

  30. National Institute on Drug Abuse. Preventing drug use among children and adolescents: a research-based guide for parents, educators, and community leaders (NIH Publication No. 04–4212(A)). 2nd ed. Bethesda, MD: National Institute on Drug Abuse, National Institutes of Health, U.S. Department of Health and Human Services; 2003.

  31. National Research Council, Institute of Medicine. Preventing mental, emotional, and behavioral disorders among young people: progress and possibilities. Washington, DC: The National Academies Press; 2009.

  32. •• Sandler I, Wolchik SA, Cruden G, Mahrer NE, Ahn S, Brincks A, et al. Overview of meta-analyses of the prevention of mental health, substance use, and conduct problems. Annu Rev Clin Psychol. 2014;10:243–73. https://doi.org/10.1146/annurev-clinpsy-050212-185524. An overview of meta-analyses on the prevention of mental health, substance use, and conduct problems indicates prevention and promotion programs can produce significant impacts to prevent multiple problem outcomes, including depression, anxiety, antisocial behavior, and substance use.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Spoth R, Trudeau L, Shin C, Ralston E, Redmond C, Greenberg M, et al. Longitudinal effects of universal preventive intervention on prescription drug misuse: three RCTs with late adolescents and young adults. Am J Public Health. 2013;103(4):665–72. https://doi.org/10.2105/AJPH.2012.301209.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Johnson EM, Porucznik CA, Anderson JW, Rolfs RT. State-level strategies for reducing prescription drug overdose deaths: Utah's prescription safety program. Pain Med. 2011;12(Suppl 2):S66–72. https://doi.org/10.1111/j.1526-4637.2011.01126.x.

    Article  PubMed  Google Scholar 

  35. Gray J, Hagemeier N, Brooks B, Alamian A. Prescription disposal practices: a 2-year ecological study of drug drop box donations in Appalachia. Am J Public Health. 2015;105(9):e89–94. https://doi.org/10.2105/ajph.2015.302689.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Spoth R, Trudeau L, Shin C, Redmond C. Long-term effects of universal preventive interventions on prescription drug misuse. Addiction. 2008;103(7):1160–8. https://doi.org/10.1111/j.1360-0443.2008.02160.x.

    Article  PubMed  Google Scholar 

  37. Champion KE, Newton NC, Barrett EL, Teesson M. A systematic review of school-based alcohol and other drug prevention programs facilitated by computers or the internet. Drug Alcohol Rev. 2013;32(2):115–23. https://doi.org/10.1111/j.1465-3362.2012.00517.x.

    Article  PubMed  Google Scholar 

  38. Faggiano F, Minozzi S, Versino E, Buscemi D. Universal school-based prevention for illicit drug use. Cochrane Database Syst Rev. 2014;12:Cd003020. https://doi.org/10.1002/14651858.CD003020.pub3.

    Article  Google Scholar 

  39. Sussman S, Arriaza B, Grigsby TJ. Alcohol, tobacco, and other drug misuse prevention and cessation programming for alternative high school youth: a review. J Sch Health. 2014;84(11):748–58. https://doi.org/10.1111/josh.12200.

    Article  PubMed  Google Scholar 

  40. • Kamarudin G, Penm J, Chaar B, Moles R. Educational interventions to improve prescribing competency: a systematic review. BMJ Open. 2013;3(8):e003291. https://doi.org/10.1136/bmjopen-2013-003291. Educational interventions can improve prescribing competency. The WHO Guide to Good Prescribing may offer a promising model for designing prescribing programs.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Bluestone J, Johnson P, Fullerton J, Carr C, Alderman J, BonTempo J. Effective in-service training design and delivery: evidence from an integrative literature review. Hum Resour Health. 2013;11:51. https://doi.org/10.1186/1478-4491-11-51.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Davis D, Galbraith R. Continuing medical education effect on practice performance: effectiveness of continuing medical education; American College of Chest Physicians evidence-based educational guidelines. Chest 2009;135(3 Suppl):42s–48s. doi:https://doi.org/10.1378/chest.08-2517.

    Article  PubMed  Google Scholar 

  43. Bloom BS. Effects of continuing medical education on improving physician clinical care and patient health: a review of systematic reviews. Int J Technol Assess Health Care. 2005;21(3):380–5.

    Article  PubMed  Google Scholar 

  44. Bordage G, Carlin B, Mazmanian PE. Continuing medical education effect on physician knowledge: effectiveness of continuing medical education; American College of Chest Physicians evidence-based educational guidelines. Chest 2009;135(3 Suppl):29s–36s. doi:https://doi.org/10.1378/chest.08-2515.

    Article  PubMed  Google Scholar 

  45. Lyon AR, Stirman SW, Kerns SE, Bruns EJ. Developing the mental health workforce: review and application of training approaches from multiple disciplines. Admin Pol Ment Health. 2011;38(4):238–53. https://doi.org/10.1007/s10488-010-0331-y.

    Article  Google Scholar 

  46. Mazmanian PE, Davis DA, Galbraith R. Continuing medical education effect on clinical outcomes: effectiveness of continuing medical education; American College of Chest Physicians evidence-based educational guidelines. Chest 2009;135(3 Suppl):49s–55s. doi:https://doi.org/10.1378/chest.08-2518.

    Article  PubMed  Google Scholar 

  47. O'Neil KM, Addrizzo-Harris DJ. Continuing medical education effect on physician knowledge application and psychomotor skills; effectiveness of continuing medical education: American College of Chest Physicians evidence-based educational guidelines. Chest. 2009;135(3 Suppl):37s–41s. https://doi.org/10.1378/chest.08-2516.

    Article  PubMed  Google Scholar 

  48. Bao Y, Pan Y, Taylor A, Radakrishnan S, Luo F, Pincus HA, et al. Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians. Health Aff (Millwood). 2016;35(6):1045–51. https://doi.org/10.1377/hlthaff.2015.1673.

    Article  Google Scholar 

  49. Surratt HL, O'Grady C, Kurtz SP, Stivers Y, Cicero TJ, Dart RC, et al. Reductions in prescription opioid diversion following recent legislative interventions in Florida. Pharmacoepidemiol Drug Saf. 2014;23(3):314–20. https://doi.org/10.1002/pds.3553.

    Article  PubMed  Google Scholar 

  50. Patrick SW, Fry CE, Jones TF, Buntin MB. Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Aff (Millwood). 2016;35(7):1324–32. https://doi.org/10.1377/hlthaff.2015.1496.

    Article  Google Scholar 

  51. Rutkow L, Chang HY, Daubresse M, Webster DW, Stuart EA, Alexander GC. Effect of Florida's prescription drug monitoring program and pill mill laws on opioid prescribing and use. JAMA Intern Med. 2015;175(10):1642–9. https://doi.org/10.1001/jamainternmed.2015.3931.

    Article  PubMed  Google Scholar 

  52. • Reifler LM, Droz D, Bailey JE, Schnoll SH, Fant R, Dart RC, et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012;13(3):434–42. https://doi.org/10.1111/j.1526-4637.2012.01327.x. Findings provide preliminary evidence that prescription drug monitoring programs may reduce opioid abuse and misuse over time.

    Article  PubMed  Google Scholar 

  53. Johnson H, Paulozzi L, Porucznik C, Mack K, Herter B. Decline in drug overdose deaths after state policy changes - Florida, 2010-2012. MMWR Morb Mortal Wkly Rep. 2014;63(26):569–74.

    PubMed  PubMed Central  Google Scholar 

  54. Kennedy-Hendricks A, Richey M, McGinty EE, Stuart EA, Barry CL, Webster DW. Opioid overdose deaths and Florida's crackdown on pill mills. Am J Public Health. 2016;106(2):291–7. https://doi.org/10.2105/ajph.2015.302953.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Lyapustina T, Rutkow L, Chang HY, Daubresse M, Ramji AF, Faul M, et al. Effect of a “pill mill” law on opioid prescribing and utilization: the case of Texas. Drug Alcohol Depend. 2016;159:190–7. https://doi.org/10.1016/j.drugalcdep.2015.12.025.

    Article  PubMed  Google Scholar 

  56. Prescription Drug Monitoring Program Center of Excellence at Brandeis University. Briefing on PDMP effectiveness. Prescription Drug Monitoring Prgram Center of Excellence at Brandeis University, Waltham, MA. 2013. http://www.pdmpexcellence.org/sites/all/pdfs/briefing_PDMP_effectiveness_april_2013.pdf.

  57. Reisman RM, Shenoy PJ, Atherly AJ, Flowers CR. Prescription opioid usage and abuse relationships: an evaluation of state prescription drug monitoring program efficacy. Subst Abuse. 2009;3:41–51.

    PubMed  PubMed Central  Google Scholar 

  58. Worley J. Prescription drug monitoring programs, a response to doctor shopping: purpose, effectiveness, and directions for future research. Issues Ment Health Nurs. 2012;33(5):319–28. https://doi.org/10.3109/01612840.2011.654046.

    Article  PubMed  Google Scholar 

  59. Substance Abuse and Mental Health Services Administration. Systems-level implementation of screening, brief intervention, and referral to treatment (Technical Assistance Publication (TAP) Series 33, HHS Publication No. (SMA) 13–4741). Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.

  60. Angus C, Latimer N, Preston L, Li J, Purshouse R. What are the implications for policy makers? A systematic review of the cost-effectiveness of screening and brief interventions for alcohol misuse in primary care. Front Pyschiatry. 2014;5:114. https://doi.org/10.3389/fpsyt.2014.00114.

    Article  Google Scholar 

  61. Humeniuk R, Ali R, Babor T, Souza-Formigoni ML, de Lacerda RB, Ling W, et al. A randomized controlled trial of a brief intervention for illicit drugs linked to the alcohol, smoking and substance involvement screening test (ASSIST) in clients recruited from primary health-care settings in four countries. Addiction. 2012;107(5):957–66. https://doi.org/10.1111/j.1360-0443.2011.03740.x.

    Article  PubMed  Google Scholar 

  62. Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and six months. Drug Alcohol Depend. 2009;99(1–3):280–95. https://doi.org/10.1016/j.drugalcdep.2008.08.003.

    Article  PubMed  Google Scholar 

  63. O'Donnell A, Anderson P, Newbury-Birch D, Schulte B, Schmidt C, Reimer J, et al. The impact of brief alcohol interventions in primary healthcare: a systematic review of reviews. Alcohol Alcohol. 2014;49(1):66–78. https://doi.org/10.1093/alcalc/agt170.

    Article  PubMed  Google Scholar 

  64. Sterling S, Valkanoff T, Hinman A, Weisner C. Integrating substance use treatment into adolescent health care. Curr Psychiatry Rep. 2012;14(5):453–61. https://doi.org/10.1007/s11920-012-0304-9.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Barbosa C, Cowell A, Bray J, Aldridge A. The cost-effectiveness of alcohol screening, brief intervention, and referral to treatment (SBIRT) in emergency and outpatient medical settings. J Subst Abuse Treat. 2015;53:1–8. https://doi.org/10.1016/j.jsat.2015.01.003.

    Article  PubMed  Google Scholar 

  66. Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med. 2016;10(2):93–103. https://doi.org/10.1097/ADM.0000000000000193.

    Article  CAS  PubMed  Google Scholar 

  67. Thomas CP, Fullerton CA, Kim M, Montejano L, Lyman DR, Dougherty RH, et al. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv. 2014;65(2):158–70. https://doi.org/10.1176/appi.ps.201300256.

    Article  PubMed  Google Scholar 

  68. •• Fullerton CA, Kim M, Thomas CP, Lyman DR, Montejano LB, Dougherty RH, et al. Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv. 2014;65(2):146–57. https://doi.org/10.1176/appi.ps.201300235. In this review of meta-analyses, systematic reviews and individual studies, methadone maintenance treatment (MMT) had a positive impact on treatment retention and illicit opioid use, especially at doses over 60 mg. There is also evidence for improvements in drug-related HIV risk behaviors, mortality, and criminality.

    Article  PubMed  Google Scholar 

  69. Jhanjee S. Evidence based psychosocial interventions in substance use. Indian J Psychol Med. 2014;36(2):112–8. https://doi.org/10.4103/0253-7176.130960.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165(2):179–87. https://doi.org/10.1176/appi.ajp.2007.06111851.

    Article  PubMed  Google Scholar 

  71. National Institute on Drug Abuse. Principles of drug addiction treatment: a research-based guide (NIH Publication No. 12–4180). 3rd ed. Bethesda, MD: National Institute on Drug Abuse, National Institutes of Health, U.S. Department of Health and Human Services; 2012.

  72. Hogue A, Henderson CE, Ozechowski TJ, Robbins MS. Evidence base on outpatient behavioral treatments for adolescent substance use: updates and recommendations 2007-2013. J Clin Child Adolesc Psychol. 2014;43(5):695–720. https://doi.org/10.1080/15374416.2014.915550.

    Article  PubMed  Google Scholar 

  73. Institute of Medicine. Psychosocial interventions for mental and substance use disorders: a framework for establishing evidence-based standards. Washington, DC: The National Academies of Press; 2015.

  74. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:Cd002207. https://doi.org/10.1002/14651858.CD002207.pub4.

    Article  Google Scholar 

  75. Tanner-Smith EE, Wilson SJ, Lipsey MW. The comparative effectiveness of outpatient treatment for adolescent substance abuse: a meta-analysis. J Subst Abus Treat. 2013;44(2):145–58. https://doi.org/10.1016/j.jsat.2012.05.006.

    Article  Google Scholar 

  76. McQueen K, Murphy-Oikonen J. Neonatal abstinence syndrome. N Engl J Med. 2016;375(25):2468–79. https://doi.org/10.1056/NEJMra1600879.

    Article  PubMed  Google Scholar 

  77. Bagley SM, Wachman EM, Holland E, Brogly SB. Review of the assessment and management of neonatal abstinence syndrome. Addict Sci Clin Pract. 2014;9(1):19. https://doi.org/10.1186/1940-0640-9-19.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Blumenthal PD, Voedisch A, Gemzell-Danielsson K. Strategies to prevent unintended pregnancy: increasing use of long-acting reversible contraception. Hum Reprod Update. 2011;17(1):121–37. https://doi.org/10.1093/humupd/dmq026.

    Article  CAS  PubMed  Google Scholar 

  79. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998–2007. https://doi.org/10.1056/NEJMoa1110855.

    Article  CAS  PubMed  Google Scholar 

  80. Brogly SB, Saia KA, Walley AY, Du HM, Sebastiani P. Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. Am J Epidemiol. 2014;180(7):673–86. https://doi.org/10.1093/aje/kwu190.

    Article  PubMed  Google Scholar 

  81. Kraft WK, Stover MW, Davis JM. Neonatal abstinence syndrome: pharmacologic strategies for the mother and infant. Semin Perinatol. 2016;40(3):203–12. https://doi.org/10.1053/j.semperi.2015.12.007.

    Article  PubMed  PubMed Central  Google Scholar 

  82. MacMullen NJ, Dulski LA, Blobaum P. Evidence-based interventions for neonatal abstinence syndrome. Pediatr Nurs. 2014;40(4):165–72. 203

    PubMed  Google Scholar 

  83. Chandler RK, Fletcher BW, Volkow ND. Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA. 2009;301(2):183–90. https://doi.org/10.1001/jama.2008.976.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. •• Carey SM, Mackin JR, Finigan MW. What works? The ten key components of drug court: research-based best practices. Drug Court Rev. 2012;8(1):6–42. Drug courts can effectively reduce recidivism and increase cost savings among diverse populations. Based on the 69 programs evaluated, the average reduction in recidivism was 32% and the average increase in cost savings was 27%.

    Google Scholar 

  85. Brown RT. Systematic review of the impact of adult drug-treatment courts. Transl Res. 2010;155(6):263–74. https://doi.org/10.1016/j.trsl.2010.03.001.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Marlowe DB. Research update on adult drug courts. Need to know. National Association of Drug Court Professionals, Alexandria, VA. 2010. https://www.ndci.org/wp-content/uploads/2016/08/Research-Update-on-Adult-Drug-Courts-NADCP_1.pdf.

  87. Marlowe DB. Research update on juvenile drug treatment courts. Need to Know. National Association of Drug Court Professionals, Alexandria, VA. 2010. https://www.ndci.org/wp-content/uploads/2016/08/Research-Update-on-Juvenile-Drug-Treatment-Courts-NADCP_1.pdf.

  88. Marlowe DB, Carey SM. Research update on family drug courts. Need to Know. National Association of Drug Court Professionals, Alexandria, VA. 2012. https://www.ndci.org/wp-content/uploads/2016/08/Reseach-Update-on-Family-Drug-Courts-NADCP.pdf.

  89. Stein DM, Deberard S, Homan K. Predicting success and failure in juvenile drug treatment court: a meta-analytic review. J Subst Abus Treat. 2013;44(2):159–68. https://doi.org/10.1016/j.jsat.2012.07.002.

    Article  Google Scholar 

  90. Centers for Disease Control and Prevention. Community-based opioid overdose prevention programs providing naloxone - United States. 2010 MMWR Morb Mortal Wkly Rep. 2012;61(6):101–5.

    Google Scholar 

  91. Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med. 2014;8(3):153–63. https://doi.org/10.1097/adm.0000000000000034.

    Article  CAS  PubMed  Google Scholar 

  92. Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174. https://doi.org/10.1136/bmj.f174.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Seal KH, Thawley R, Gee L, Bamberger J, Kral AH, Ciccarone D, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health. 2005;82(2):303–11. https://doi.org/10.1093/jurban/jti053.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Piper TM, Stancliff S, Rudenstine S, Sherman S, Nandi V, Clear A, et al. Evaluation of a naloxone distribution and administration program in New York City. Subst Use Misuse. 2008;43(7):858–70.

    Article  PubMed  Google Scholar 

  95. Bennett AS, Bell A, Tomedi L, Hulsey EG, Kral AH. Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania. J Urban Health. 2011;88(6):1020–30. https://doi.org/10.1007/s11524-011-9600-7.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Gordis L. Epidemiology. Philadelphia, PA: Elsevier Saunders; 2014.

    Google Scholar 

  97. Nation M, Crusto C, Wandersman A, Kumpfer KL, Seybolt D, Morrissey-Kane E, et al. What works in prevention. Principles of effective prevention programs. Am Psychol. 2003;58(6–7):449–56.

    Article  PubMed  Google Scholar 

  98. National Center on Addiction and Substance Abuse at Columbia University. Adolescent substance use. America's #1 public health problem. New York, NY: National Center on Addiction and Substance Abuse at Columbia University; 2011.

  99. Miller T, Hendrie D. Substance abuse prevention dollars and cents: a cost-benefit analysis (DHHS Pub. No. (SMA) 07–4298). Rockville, MD: Center for Substance Abuse Prevention, Substance Abuse and Mental Health Services Administration; 2008.

  100. Butterfoss FD, Cohen L. Prevention works. Health Promot Pract. 2009;10(2 Suppl):81s–5s. https://doi.org/10.1177/1524839909336104.

    Article  PubMed  Google Scholar 

  101. Haegerich TM, Paulozzi LJ, Manns BJ, Jones CM. What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose. Drug Alcohol Depend. 2014;145:34–47. https://doi.org/10.1016/j.drugalcdep.2014.10.001.

    Article  PubMed  PubMed Central  Google Scholar 

  102. U.S. Department of Health and Human Services. Addressing prescription drug abuse in the United States: current activities and future opportunities. Behavioral Health Coordinating Committee, Prescription Drug Abuse Subcommittee, U.S. Department of Health and Human Services, Washington, DC. 2013. http://www.cdc.gov/drugoverdose/pdf/hhs_prescription_drug_abuse_report_09.2013.pdf.

  103. Centers for Disease Control and Prevention. Prescription drug monitoring programs (PDMPs). 2016. http://www.cdc.gov/drugoverdose/pdmp/. Accessed 7 May 2016.

  104. Prescription Drug Monitoring Program Training and Technical Assistance Center. Prescription drug monitoring frequently asked questions (FAQ). http://www.pdmpassist.org/content/prescription-drug-monitoring-frequently-asked-questions-faq. Accessed 7 May 2016.

  105. Public Health Law Program, Office for State, Tribal, Local and Territorial Support, Centers for Disease Control and Prevention Menu of pain management clinic regulation. Centers for Disease Control and Prevention, Atlanta, GA. 2012. https://www.cdc.gov/phlp/docs/menu-pmcr.pdf.

  106. National Alliance for Model State Drug Laws. Part 2: state regulation of pain clinics and legislative trends relative to regulating pain clinics. Prescription drug abuse, addiction and diversion: overview of state legislative and policy initiatives; a three part series. National Alliance for Model State Drug Laws, Charlottesville, VA. 2014. http://www.namsdl.org/library/8867EBE1-19B9-E1C5-316C1FDCB35571A5/.

  107. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007;11(9):1–171, iii-iv.

  108. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies — tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–6. https://doi.org/10.1056/NEJMp1402780.

    Article  PubMed  Google Scholar 

  109. Reif S, George P, Braude L, Dougherty RH, Daniels AS, Ghose SS, et al. Residential treatment for individuals with substance use disorders: assessing the evidence. Psychiatr Serv. 2014;65(3):301–12. https://doi.org/10.1176/appi.ps.201300242.

    Article  PubMed  Google Scholar 

  110. Galanter M, Dermatis H, Post S, Sampson C. Spirituality-based recovery from drug addiction in the twelve-step fellowship of narcotics anonymous. J Addict Med. 2013;7(3):189–95. https://doi.org/10.1097/ADM.0b013e31828a0265.

    Article  PubMed  Google Scholar 

  111. Clark RE, Baxter JD, Aweh G, O'Connell E, Fisher WH, Barton BA. Risk factors for relapse and higher costs among medicaid members with opioid dependence or abuse: opioid agonists, comorbidities, and treatment history. J Subst Abus Treat. 2015;57:75–80. https://doi.org/10.1016/j.jsat.2015.05.001.

    Article  Google Scholar 

  112. Weiss RD, Potter JS, Griffin ML, Provost SE, Fitzmaurice GM, McDermott KA, et al. Long-term outcomes from the national drug abuse treatment clinical trials network prescription opioid addiction treatment study. Drug Alcohol Depend. 2015;150:112–9. https://doi.org/10.1016/j.drugalcdep.2015.02.030.

    Article  PubMed  PubMed Central  Google Scholar 

  113. ACOG Committee Opinion No. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol 2012;119(5):1070–6. doi:https://doi.org/10.1097/AOG.0b013e318256496e.

  114. Warren MD, Miller AM, Traylor J, Bauer A, Patrick SW. Implementation of a statewide surveillance system for neonatal abstinence syndrome - Tennessee. 2013 MMWR Morb Mortal Wkly Rep. 2015;64(5):125–8.

    PubMed  Google Scholar 

  115. Heil SH, Jones HE, Arria A, Kaltenbach K, Coyle M, Fischer G, et al. Unintended pregnancy in opioid-abusing women. J Subst Abus Treat. 2011;40(2):199–202. https://doi.org/10.1016/j.jsat.2010.08.011.

    Article  Google Scholar 

  116. Dumont DM, Brockmann B, Dickman S, Alexander N, Rich JD. Public health and the epidemic of incarceration. Annu Rev Public Health. 2012;33:325–39. https://doi.org/10.1146/annurev-publhealth-031811-124614.

    Article  PubMed  PubMed Central  Google Scholar 

  117. McClelland GM, Elkington KS, Teplin LA, Abram KM. Multiple substance use disorders in juvenile detainees. J Am Acad Child Adolesc Psychiatry. 2004;43(10):1215–24. https://doi.org/10.1097/01.chi.0000134489.58054.9c.

    Article  PubMed  PubMed Central  Google Scholar 

  118. National Institute of Drug Abuse. Principles of drug abuse treatment for criminal justice populations: a research-based guide (NIH Publication No. 11–5316). Bethesda, MD: National Institute on Drug Abuse, National Institutes of Health, U.S. Department of Health and Human Services; 2014.

  119. National Institute of Justice. Drug courts. 2015. http://www.nij.gov/topics/courts/drug-courts/pages/welcome.aspx. Accessed 8 May 2016.

  120. Sheidow AJ, Jayawardhana J, Bradford WD, Henggeler SW, Shapiro SB. Money matters: cost effectiveness of juvenile drug court with and without evidence-based treatments. J Child Adolesc Subst. 2012;21(1):69–90. https://doi.org/10.1080/1067828x.2012.636701.

    Article  Google Scholar 

  121. Kim D, Irwin KS, Khoshnood K. Expanded access to naloxone: options for critical response to the epidemic of opioid overdose mortality. Am J Public Health. 2009;99(3):402–7. https://doi.org/10.2105/ajph.2008.136937.

    Article  PubMed  PubMed Central  Google Scholar 

  122. Wheeler E, Jones TS, Gilbert MK, Davidson PJ. Opioid overdose prevention programs providing naloxone to laypersons - United States. 2014 MMWR Morb Mortal Wkly Rep. 2015;64(23):631–5.

    PubMed  Google Scholar 

  123. Fairbairn N, Coffin PO, Walley AY. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: challenges and innovations responding to a dynamic epidemic. Int J Drug Policy. 2017;46:172–9. https://doi.org/10.1016/j.drugpo.2017.06.005.

    Article  PubMed  PubMed Central  Google Scholar 

  124. Bazazi AR, Zaller ND, Fu JJ, Rich JD. Preventing opiate overdose deaths: examining objections to take-home naloxone. J Health Care Poor Underserved. 2010;21(4):1108–13. https://doi.org/10.1353/hpu.2010.0935.

    Article  PubMed  PubMed Central  Google Scholar 

  125. Maxwell S, Bigg D, Stanczykiewicz K, Carlberg-Racich S. Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. J Addict Dis. 2006;25(3):89–96.

    Article  PubMed  Google Scholar 

  126. Galea S, Worthington N, Piper TM, Nandi VV, Curtis M, Rosenthal DM. Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence from a pilot study in New York City. Addict Behav. 2006;31(5):907–12.

    Article  PubMed  Google Scholar 

  127. Green TC, Heimer R, Grau LE. Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States. Addiction. 2008;103(6):979–89. https://doi.org/10.1111/j.1360-0443.2008.02182.x.

    Article  PubMed  PubMed Central  Google Scholar 

  128. Tobin KE, Sherman SG, Beilenson P, Welsh C, Latkin CA. Evaluation of the staying alive programme: training injection drug users to properly administer naloxone and save lives. Int J Drug Policy. 2009;20(2):131–6. https://doi.org/10.1016/j.drugpo.2008.03.002.

    Article  PubMed  Google Scholar 

  129. Enteen L, Bauer J, McLean R, Wheeler E, Huriaux E, Kral AH, et al. Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health. 2010;87(6):931–41. https://doi.org/10.1007/s11524-010-9495-8.

    Article  PubMed  PubMed Central  Google Scholar 

  130. Wagner KD, Valente TW, Casanova M, Partovi SM, Mendenhall BM, Hundley JH, et al. Evaluation of an overdose prevention and response training programme for injection drug users in the skid row area of Los Angeles. California Int J Drug Policy. 2010;21(3):186–93. https://doi.org/10.1016/j.drugpo.2009.01.003.

    Article  PubMed  Google Scholar 

  131. Lankenau SE, Wagner KD, Silva K, Kecojevic A, Iverson E, McNeely M, et al. Injection drug users trained by overdose prevention programs: responses to witnessed overdoses. J Community Health. 2013;38(1):133–41. https://doi.org/10.1007/s10900-012-9591-7.

    Article  PubMed  PubMed Central  Google Scholar 

  132. Behar E, Santos G-M, Wheeler E, Rowe C, Coffin PO. Brief overdose education is sufficient for naloxone distribution to opioid users. Drug Alcohol Depend. 2015;148:209–12. https://doi.org/10.1016/j.drugalcdep.2014.12.009.

    Article  PubMed  Google Scholar 

Download references

Funding

The work was supported in part by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) under award R24DA036409. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH.

Author information

Authors and Affiliations

  1. College of Public Health, East Tennessee State University, Johnson City, TN, USA

    Stephanie M. Mathis, Angela Hagaman & Robert P. Pack

  2. Center for Prescription Drug Abuse Prevention and Treatment, East Tennessee State University, Johnson City, TN, USA

    Stephanie M. Mathis, Nicholas Hagemeier, Angela Hagaman & Robert P. Pack

  3. Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN, USA

    Nicholas Hagemeier

  4. Tennessee Department of Health, Nashville, TN, USA

    John Dreyzehner

Authors
  1. Stephanie M. Mathis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas Hagemeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angela Hagaman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John Dreyzehner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert P. Pack
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert P. Pack.

Ethics declarations

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on The Global Epidemic

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mathis, S.M., Hagemeier, N., Hagaman, A. et al. A Dissemination and Implementation Science Approach to the Epidemic of Opioid Use Disorder in the United States. Curr HIV/AIDS Rep 15, 359–370 (2018). https://doi.org/10.1007/s11904-018-0409-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-018-0409-9

Keywords

Search

Navigation